SEC Comment Letter for Monopar Therapeutics (MNPR) (CIK 0001645469) (MNPR) — Jan 10, 2020
Monopar Therapeutics (MNPR) (CIK 0001645469)
Date: Jan. 10, 2020 · CIK: 0001645469 · Accession: 0000000000-20-000259
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-235791
Letter
January 10, 2020 Chandler D. Robinson, MD MBA MSc Chief Executive Officer Monopar Therapeutics 1000 Skokie Blvd., Suite 350 Wilmette, IL 60091 Re:Monopar Therapeutics Inc. Registration Statement on Form S-3 Filed January 3, 2020 File No. 333-235791 Dear Dr. Robinson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert Rupp, Esq.
Show Raw Text
January 10, 2020
Chandler D. Robinson, MD MBA MSc
Chief Executive Officer
Monopar Therapeutics
1000 Skokie Blvd., Suite 350
Wilmette, IL 60091
Re:Monopar Therapeutics Inc.
Registration Statement on Form S-3
Filed January 3, 2020
File No. 333-235791
Dear Dr. Robinson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Robert Rupp, Esq.